Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma

Journal of Clinical Oncology

Volumn 24, Issue 22, 2006, Pages 3644-3650

  Mamelak, Adam N ^a   Rosenfeld, Steven ^a   Bucholz, Richard ^a   Raubitschek, Andrew ^a   Nabors, L Burt ^a   Fiveash, John B ^a   Shen, Sui ^a   Khazaeli, M B ^a   Colcher, David ^a   Liu, An ^a   Osman, Medhat ^a   Guthrie, Bart ^a   Schade Bijur, Susan ^a   Hablitz, Diana M ^a   Alvarez, Vernon L ^a   Gonda, Matthew A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; PEPTIDE; RADIOACTIVE IODINE; TM 601; UNCLASSIFIED DRUG; CHLOROTOXIN; RADIOPHARMACEUTICAL AGENT; SCORPION VENOM;

ADULT; ARTICLE; BRAIN HEMATOMA; BRAIN VENTRICLE DILATATION; CANCER GRADING; CATHETERIZATION; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRANIOTOMY; CYTOREDUCTIVE SURGERY; DOSIMETRY; DRUG DISTRIBUTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG UPTAKE; DYSARTHRIA; FEMALE; FOLLOW UP; GLIOBLASTOMA; GLIOMA; GRAND MAL SEIZURE; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MENTAL INSTABILITY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SINGLE DRUG DOSE; SOMNOLENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR RECURRENCE; AGED; BRACHYTHERAPY; BRAIN TUMOR; KARNOFSKY PERFORMANCE STATUS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; RADIATION DOSE; RADIOGRAPHY; RADIOMETRY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL; TIME;

ADULT; AGED; BRACHYTHERAPY; BRAIN NEOPLASMS; FEMALE; GLIOMA; HUMANS; IODINE RADIOISOTOPES; KARNOFSKY PERFORMANCE STATUS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; SCORPION VENOMS; SURVIVAL ANALYSIS; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 33747059059     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.4569     Document Type: Article

References (27)

1. National Cancer Institute: Adult brain tumors (PDQ): Treatment. http://www.nci.nih.gov/cancertopics/pdq/treatment/adultbrain/healthprofessional
2. Accelerate Brain Cancer Cure: Statistics. http://www.abc2.org/statistics. shtml
3. Stewart LA: Chemotherapy in adult-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 359:1011-1018, 2002
4. Grossman SA, Batara JF: Current management of glioblastoma multiforme. Semin Oncol 31: 635-644, 2004
5. Parney IF, Chang SM: Current chemotherapy for glioblastoma. Cancer J 9:149-156, 2003
6. DeBin JA, Maggio JE, Strichartz GR: Purification and characterization of chlorotoxin, a chloride channel ligand from the venom of the scorpion. Am J Physiol 264:C361-C369, 1993
7. Soroceanu L, Gillespie Y, Khazaeli MB, et al: Use of chlorotoxin for targeting of primary brain tumors. Cancer Res 58:4871-4879, 1998
8. 131I-chlorotoxin for targeted radiotherapy in glioma-bearing mice. J Neurooncol 71:113-119, 2005
9. Grimes CA, Gonda MA, Alvarez VL: TM-601 targets human cancer cells via a phosphatidylinositol phosphate in lamellipodia. J Clin Oncol 23:850s, 2005 (abstr 9556)
10. Woltanski KP, Besch W, Keilacker H, et al: Radioiodination of peptide hormones and immunoglobulin preparations: Comparison of the chloramines T and iodogen method. Exp Clin Endocrinol 95:39-46, 1990
11. Karnofsky D, Abelman W, Craver L, et al: The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1:634-656, 1948
12. 131I-TM-601. J Nucl Med 46:580-586, 2005
13. Shen S, Forero A, LoBuglio AF, et al: Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. J Nucl Med 46:642-651, 2005
14. Sabin MG: MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 37:538-546, 1996
15. Burger PC, Heinz ER, Shibata T, et al: Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurg 68:698-704, 1988
16. Harsh GR: Management of recurrent gliomas, in Berger MS, Wilson CB (eds): The Gliomas. Philadelphia, PA, WB Saunders, 1999, p 649
17. Sgouros G: Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations. J Nucl Med 34:689-694, 1993
18. Shen S, DeNardo GL, Sgouros G, et al: Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med 40:2102-2106, 1999
19. Lyons SA, O'Neal J, Sontheimer H: Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia 39:162-173, 2002
20. Emami B, Lyman J, Brown A, et al: Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109-122, 1991
21. Goldenberg DM: Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 43:693-713, 2002
22. DeNardo GL: Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs). Semin Nucl Med 35:202-211, 2005
23. Metso S, Jaatinen P, Huhtala H, et al: Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol (Oxf) 61:641-648, 2004
24. Leslie WD, Ward L, Salamon EA, et al: A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab 88:978-983, 2003
25. Akabani G, Reardon DA, Coleman RE, et al: Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant glioma: A phase II study. J Nucl Med 46:1042-1051, 2005
26. Shen S, Mamelak A, Raubitschek A, et al: Dosimetry of phase I/II study of intracavitary administered I-131-TM-601 peptide in patients with recurrent high-grade glioma. Int J Radiat Oncol Biol Phys 60:S259, 2004 (suppl, abstr)
27. Lamborn KR, Chang SM, Prados MD: Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis. Neuro-oncol 6:227-235, 2004